REGOTORI
Regimen
- Experimental
- Regorafenib (dose-optimized) + toripalimab (PD-1 antibody)
- Control
- single-arm
Population
MSS/pMMR metastatic CRC, refractory; China-led phase Ib/II trial (N=not specified).
Key finding
3L+ MSS mCRC (regorafenib 80mg + toripalimab PD-1 antibody): ORR 15.2%, DCR 36.4%; mPFS 2.1 mo; mOS 15.5 mo; liver metastases: ORR 8.7% vs lung-only: ORR 100% (3/3); gut microbiome analysis suggests Fusobacterium abundance correlates with response; grade 3 TRAEs 38.5%
Source: PMID 34622226